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Abstract
Apelin is a peptide ligand for an orphan G-protein coupled receptor (APJ receptor) and serves as a critical gradient for
migration of mesodermal cells fated to contribute to the myocardial lineage. The present study was designed to establish
a robust cardiac differentiation protocol, specifically, to evaluate the effect of apelin on directed differentiation of mouse
and human embryonic stem cells (mESCs and hESCs) into cardiac lineage. Different concentrations of apelin (50, 100,
500 nM) were evaluated to determine its differentiation potential. The optimized dose of apelin was then combined with
mesodermal differentiation factors, including BMP-4, activin-A, and bFGF, in a developmentally specific temporal sequence
to examine the synergistic effects on cardiac differentiation. Cellular, molecular, and physiologic characteristics of the
apelin-induced contractile embryoid bodies (EBs) were analyzed. It was found that 100 nM apelin resulted in highest
percentage of contractile EB for mESCs while 500 nM had the highest effects on hESCs. Functionally, the contractile
frequency of mESCs-derived EBs (mEBs) responded appropriately to increasing concentration of isoprenaline and diltiazem.
Positive phenotype of cardiac specific markers was confirmed in the apelin-treated groups. The protocol, consisting of
apelin and mesodermal differentiation factors, induced contractility in significantly higher percentage of hESC-derived EBs
(hEBs), up-regulated cardiac-specific genes and cell surface markers, and increased the contractile force. In conclusion, we
have demonstrated that the treatment of apelin enhanced cardiac differentiation of mouse and human ESCs and exhibited
synergistic effects with mesodermal differentiation factors.
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Introduction
Myocardial infarction, a common presentation of ischemic
heart disease, results in an irreversible necrosis of cardiomyocytes
[1–3]. This usually results from an acute interruption of blood
supply, which is most often caused by atherosclerotic plaque
rupture with thrombus formation in a coronary vessel [1]. The
most common sequela of this disease process is heart failure (HF),
which is the leading cause of hospital admission in the United
States for both men and women [4,5]. With approximately
400,000 annual incidences, coronary heart disease is responsible
for 1 in 6 deaths in the US in 2008 [2]. Of the 3 million people
suffering from advanced HF, 15–25% await heart transplantation.
However, heart organ donation is limited to 1,000 recipients per
year [6]. Despite advances in medical, percutaneous, and surgical
interventions during the past decades, the 5-year survival of
patients with advanced HF still remains around 50%. Therefore,
an alternative therapeutic strategy aimed at sustained and
permanent myocardial restoration is necessary.
Heart failure, resulting from myocardial injury and subsequent
contractile dysfunction, is due to the limited mitotic capacity of
terminally differentiated cardiomyocytes [4]. During this disease
process, cardiac progenitor cells have been reported to migrate to
the injury site, differentiate into cardiomyocytes, and eventually,
regenerate the myocardium [7–8]. However, the native population
of cardiac progenitor cells is extremely limited and decreases
significantly during the aging process, compromising its repair
potential [9]. In order to replace the lost cardiomyocytes and
regenerate the myocardium, cell transplantation is emerging as
a potentially useful therapeutic strategy to restore cardiac function.
Embryonic stem cells (ESCs) represent a promising source of
pluripotent stem cells for cardiac regeneration capable of self-
renewal and robust cardiac differentiation [10]. Multiple pre-
clinical research efforts have shown the beneficial effects of ESC
transplantation therapy in myocardial regeneration [11,12];
however, its clinical implementation has been hampered by
teratoma formation of the undifferentiated ESCs [11]. Although
cardiac differentiation protocols have reported high percentage of
contractile ESC-derived embryoid bodies (EBs), the percentage of
cardiac cells remain low, the effects of the differentiation factors
are unclear, and the results are difficult to duplicate [13–15]. In
a recently reported protocol, induction of hESCs with BMP-4,
activin-A and basic fibroblast growth factor (bFGF) generated
cardiac, endothelial and vascular smooth muscle cells [16]. The
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38328differentiated EBs exhibited contractile cardiac phenotype and
cardiac-specific markers.
In this study, we incorporate a novel peptide, apelin, a newly
identified peptide ligand for an orphan apelin G-protein coupled
receptor (APJ receptor) with 31% sequence similarity to the
angiotensin receptor AT1 [17–18]. During cardiac development,
apelin serves as a critical gradient for migration of mesodermal
cells fated to contribute to the myocardial lineage [19,20].
Zebrafish pregastrulae embryos are shown to express AT1 early
in the blastoderm margin and later in regions where cardiac
progenitor cells reside. Apelin, a ligand expression, is restricted to
this midline, and depletion of the AT1 receptor results in a reduced
number of myocardial progenitor cells and absence of an
organized cardiac structure. After a myocardial infarction, an
up-regulated expression of apelin at the injury site of the left
ventricle has been reported, resulting in the recruitment of the
cKit+/Flk1+ cardiac progenitor cells and myocardial regeneration
[21]. Furthermore, these APJ transcripts are also detected in the
developing heart during embryonic growth of mouse and frog,
suggesting the involvement of apelin in embryonic myocardial
development, regeneration, and function [22–23]. This study
investigates the effects of apelin in enhancing cardiac differenti-
ation of mouse and human ESCs through selective aggregation of
cardiac lineage committed cells.
Materials and Methods
All reactions were done at room temperature unless otherwise
noted.
Cells
Mouse ESC (mESC) line, TL1, was derived from 129Sv/J mice
(kindly given by collaborator Dr. Thomas Quertermous) [24] and
maintained on a confluent feeder layer of irradiated mouse
embryonic fibroblasts CF-1 line (MEF, GlobalStem, Inc.) in the
high glucose Dulbecco’s Modified Essential Medium (DMEM,
Gibco, Carlsbad, CA) with 15% fetal bovine serum (FBS,
Hyclone, Logan, Utah), 1% non-essential amino acids, 1%
penicillin/streptomycin, 0.05 mM b-mercaptoethanol (b-ME,
Millipore, Billerica, MA) and 1000 U/ml leukaemia inhibitory
factor (LIF, Millipore). Human ESC (hESC) line, H7 (commer-
cially available at WiCell, Madison, WI), was maintained with
a feeder layer of irradiated MEF CF-1 line at 25% confluency on
0.2% gelatin-coated surfaces. Human ESCs were cultured in the
KnockOut DMEM (Gibco) with 20% KnockOut Serum Replacer
(Gibco), 1% non-essential amino acids, 1% penicillin/streptomy-
cin, 0.05 mM b-ME, 2 mM L-glutamine (Gibco) and 4 ng/ml
basic fibroblast growth factor (bFGF, Invitrogen). Cells derived
from 20–60 passages were used for the study. The cultures were
grown at 37uC and 5% CO2 in a humidified normoxic
environment.
Mouse and Human ESC Cardiac Differentiation Cell
Culture Methods
To induce differentiation, mESCs were suspended in mouse
basal differentiation medium containing 20% FBS, 1% non-
essential amino acids, 1% penicillin/streptomycin and 0.1 mM b-
ME in DMEM. Then drops (20 mL) of 500 cells were placed on
the internal surface of a 100-mm tissue culture dish lids containing
phosphate buffer saline (PBS) [25]. After 2 days, the mESCs were
aggregated in hanging drops called embryoid bodies (EBs) and
were transferred to suspension culture in 96 well ultra low
attachment plates for an additional 3 days in mouse basal
differentiation medium to enhance the aggregation. 5 day-old
mESC-derived EBs (mEBs) were then plated onto 0.1% gelatin-
coated 48-well tissue culture plates at a density of one mEB per
Figure 1. Timeline. Our combined protocols for both mESCs and hESCs include the addition of apelin (grey) to the reported protocols (green).
Protocols A and B are indicated in the green boxes without apelin treatment.
doi:10.1371/journal.pone.0038328.g001
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differentiation media at this point (day 0). The timeline for the
differentiation is shown in Figure 1.
For hESC differentiation studies, hESC colonies were detached
from the Petri dish by using collagenase type IV (Gibco) without
dissociating the hESC into single cell suspension. The MEF and
hESC colonies were separated by low speed centrifugation (0.5
RPM). Pure population of hESC colonies were allowed to
aggregate to form EBs (,2000 cells/colony) by incubating in 6
well ultra low attachment plates for 2 days in human basal
differentiation medium containing 20% FBS, 1% non-essential
amino acids, 1% penicillin/streptomycin, 0.05 mM b-ME, 2 mM
L-glutamine in KnockOut DMEM. After 2 days, hESC-derived
EBs (hEBs) were plated onto 0.2% gelatin-coated 12-well plates at
a density of ,15 hEBs per well. Various differentiation factors
were added into the basal differentiation media at day 0 (Figure 1).
Effects of Apelin on mouse and human ESC Cardiac
Differentiation
Upon EB formation, the effects of apelin-13 concentration
(apelin, 0, 50, 100, 500 nM) on the percentage of contractile EBs,
production of cardiac troponin-T (cTNT), connexin 43, and a-
actinin (immunohistochemistry, n=3) and gene expression of
cardiac markers (rt-PCR, n=5) were determined for both mESCs
and hESCs up to 28 days. The cell culture medium was changed
daily. The percentage of contractile EBs was measured by the
number of EBs that showed any degree of contractility divided by
the total number of EBs in culture. Chronotropic responses of
mEBs to pharmacologic treatment was also examined (n=5).
Synergistic Effects of Apelin and Mesodermal
Differentiation Factors on human ESC Cardiac
Differentiation
We adapted and modified two reported cardiac differentiation
protocols (Protocols A and B) to examine the synergistic effects of
apelin on cardiac differentiation [13,16]. In Protocol A, the
differentiation of hESC-derived EBs (hEBs) was induced with
addition of 10 ng/ml BMP-4, 6 ng/ml activin-A and 5 ng/ml
bFGF for 5 days, followed by a 4 day treatment period with
10 ng/ml vascular endothelial growth factor (VEGF) and 150 ng/
ml dickkopf-related protein 1 (Dkk1). Afterwards, cultures were
maintained in 10 ng/ml VEGF and 5 ng/ml Dkk1 to develop
mature cardiac phenotype. Basal medium containing 20% FBS
was used for the entire culture period in this study. Optimal apelin
dosage at 500 nM was administered to Protocol A (Combined
Protocol A) from days 0 to 14.
In order to eliminate the unconfined biochemical composition
found in the FBS, Protocol B examined cardiac differentiation in
a FBS-reduced medium. In Protocol B, single cells of hESCs were
aggregated in V-shape well with brief centrifugation in a serum
free RPMI1640 basal medium for 2 days with 25 ng/ml BMP-4
and 5 ng/ml bFGF. After the aggregation phase, hEBs were
incubated with 20% FBS along with 500 nM of apelin in
RPMI1640 basal medium for 2 days. The hEBs were then plated
onto matrigel-coated culture surface in a serum free media with
500 nM apelin for 1 additional day. The total exposure of hEBs to
apelin was 3 days in Combined Protocol B. The final treatment
groups included the following: 1) basal differentiation medium
containing 20% FBS, 2) Protocol A, 3) Protocol B, 4) apelin alone,
5) Combined Protocol A, and 6) Combined Protocol B. Percentage
of contractile EBs (n=4), immunohistology of cardiac phenotype
(n=3), and RT-PCR of cardiac-specific genes (n=5) were assessed
serially up to 32 days. Furthermore, in single hESC-derived
Figure 2. Effect of different concentrations of apelin on mEBs. (A) Percentage of beating EBs, (B) Immunohistochemistry of cardiac troponin T
(cTNT, red) and a-actinin on day 14 (red, and blue stain: Hoechst nuclear stain), (C) Quantitative RT-PCR demonstrates significant increase of Isl1 on
day 5 and of Nkx2.5 and APJ on day 7 (*p,0.05), and a trend of increase in GATA4 expression.
doi:10.1371/journal.pone.0038328.g002
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2+ imaging was performed on
day 21 to measure calcium transients (n=6) and atomic force
microscopy (AFM) was conducted on day 28 to measure the
contractile force (n=4).
Chronotropic Effects of Cardiotonic Drugs
The mEBs were plated onto gelatin coated 48-well plates and
allowed to differentiate. One day before the experiment, the cells
were fed with 0.5 ml/well differentiation medium and contractile
areas were delineated for longitudinal observation. On the day of
experiment, the contractile frequency for each area was measured
by visual inspection before the addition of the drugs. To examine
their pharmacological responses, diltiazem, a calcium channel
blocker, and isoprenaline, a b1-adrenoreceptor agonist, were
added to the cell culture. The cell cultures were then incubated at
37uC without shaking for 20–30 minutes. The contractile
frequency per minute was measured visually. Increasing drug
doses (from 0 to 10
25 M) were added in the cell cultures followed
Figure 3. Pharmacologic response of mEBs. (A) Effect of diltiazem (calcium channel blocker) and (B) Isoprenaline (b1-adrenoreceptor agonist) on
mESC-derived cardiomyocytes on day 14 of differentiation (*p,0.05). Corresponding negative and positive chronotropy was observed for diltiazem
and isoprenaline, respectively.
doi:10.1371/journal.pone.0038328.g003
Figure 4. Effects of apelin on hEBs contractility and production of cardiac troponin-T, connexin 43 and a-sarcomeric actin. (A)
Combined Protocol A demonstrates highest percentage of contractile hEBs compared to other protocols (*p,0.05 for Combined Protocol A vs. other
treatment groups), (B) Immunohistochemistry of cardiac troponin T (red stain), a-actinin (green stain), and connexin-43 (green stain) in 500 nM apelin
only group on day 21 (blue stain: Hoechst nuclear stain).
doi:10.1371/journal.pone.0038328.g004
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then monitored for each drug concentration after the incubation
period.
Immunohistochemistry
Cells were fixed with PBS containing 4% paraformaldehyde
(Sigma) for 10 minutes at room temperature. After washing with
PBS, the cells were permeated using 0.25% Triton X-100 (Sigma)
for 10 minutes, then blocked with 10% goat serum (Sigma) for
1 hour at room temperature. Finally, the primary antibodies were
incubated for 45 minutes at room temperature. Monoclonal
antibodies used in this study included cardiac troponin T (dilution
1:200, Santa Cruz Biotechnology, Inc., Santa Cruz, CA),
Connexin 43 (Sigma), and a-sarcomeric actinin (dilution 1:500,
Santa Cruz Biotechnology). Cells were subsequently counter-
stained with Hoechst 33342 (Invitrogen) for nuclear staining.
Preparations were examined using fluorescence microscope
(Nikon, Japan).
Figure 5. Synergistic effects of apelin on hESC cardiac gene expression using Combined Protocol A. (A) Down-regulation of Mesp-1 is
observed in all 4 protocols, (B) Nkx2.5 (an early cardiac transcriptional factor, indicative of cardiac progenitor phenotype) is up-regulated in the
combined protocol A at day 16, (C) cTNT (cardiac troponin T, a muscle contractility regulatory protein, indicative of a mature cardiac phenotype) is
up-regulated in the combined protocol A at day 16, (D) ANP (atrial natriuretic peptide, a protein peptide secreted by mature cardiomyocyte,
indicative of a mature cardiac phenotype) is up-regulated after day 16, (E) MHC (myosin heavy chain, a muscular motor protein, indicative of a mature
cardiac phenotype) is up-regulated at day 32, and (F) MLC (myosin light chain, a muscular motor protein, indicative of a mature cardiac phenotype) is
up-regulated over time for all groups (*p,0.05 Combined Protocol A vs. other treatment groups).
doi:10.1371/journal.pone.0038328.g005
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Gene expression was measured by reverse transcription
followed by real-time polymerase chain reaction (rt-PCR). Primers
were designed for mESCs (Nkx2.5, Isl1, and APJ) and hESCs
(Mesp-1, Nkx2.5, atrial natriuretic peptide (ANP), cardiac
troponin T (cTNT), myosin light chain (MLC) and myosin heavy
chain (MHC)). Total RNA was isolated (n=4) using the TrizolH
extraction method (Invitrogen, Carlsbad, CA). The isolated RNA
was reverse transcribed into cDNA using the SuperScript
TM First-
Strand Synthesis System (Invitrogen) and amplified using iQ
SYBR Green Supermix (Applied Biosystems) and StepOne Plus
Real-Time PCR Detection System (Applied Biosystems). All genes
were amplified for 40 cycles. Specific gene expression was first
normalized to GAPDH and then compared to the control groups.
Live-Cell Calcium
2+ Imaging
Beating EBs from each group were mechanically detached from
the tissue culture surface and dissociated with TrypLE Express
(Invitrogen) for 5 minutes. Single cells were allowed to attach onto
gelatinized glass coverslip (Lab-Tek, Thermo Scientific/Nunc,
Rochester, NY) for 5 days prior to the imaging. On the day of
imaging, cells were stained with 5 mM Fluo-4 AM and 0.02%
Pluronic F-127 (Molecular Probe) for 15 minutes, and fluores-
cence signal from intracellular Ca
2+ was monitored using fast line
scanning (1.92 ms/line) on a confocal microscope (LSM 510
Meta, Carl Zeiss) with a X63 lens (NA=1.4) [26].
Flow Cytometry
At week 1, 2 and 4, hEBs were mechanically detached from the
culture surface and dissociated using TryLE Express (Invitrogen)
for 5 minutes. Cells were fixed and permeabilized with PharMin-
gen Perm/Fix solution for 30 minutes at 4uC, and incubated with
primary antibody against human cTNT (1:200, Abcam) overnight
at 4uC. The next day, cells were stained with fit-C conjugated
secondary antibody (1:500, Abcam) for 30 minutes at room
temperature. Expression of markers was determined by FACS
Calibur (BD Bioscience) and FlowJo software (Tree Star) to
quantify the percentage of cTNT
+ cells.
Atomic Force Microscopy
The contractile hEBs were mechanically detached from the
tissue culture surface and dissociated with TrypLE Express for
Figure 6. Synergistic effects of apelin on hESC in serum-reduced Combined Protocol B. (A) Significant up-regulation of cTNT gene
expression is seen in Combined Protocol B, (B) Significant increase of cTNT
+ cells is observed in Combined Protocol B, (C) No significant difference in
Ca
2+ transient is seen in the hESC-derived cardiac cells between Combined Protocol B and control groups, and (D) Significant increase in peak
contractile force was observed in Combined Protocol B vs. Protocol B (*p,0.05).
doi:10.1371/journal.pone.0038328.g006
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plate for 3 days prior to imaging. The culture media of cells were
changed to a medium containing 89% Tyrode’s buffer, 10% FEB
and 1% antibiotic-antimycotic (Cellgro, Mediatech) before the
experiment. Cells were maintained at 36uC during the measure-
ment. The contractile force of the cells was measured by AFM
(MFP-3D Bio, Asylum Research) using a silicon nitride cantilever
(spring constants ,0.1 N/m, PPP-ContAu, NanoSensors). Cells
were gently contacted by the cantilever tip with 400 pN of force.
The cantilever tip remained in the position without Z-piezo
feedback and the deflection data were collected at a sample rate of
1 kHz for two minutes. The deflection trajectory was converted to
force trajectory by multiplying by the spring constant and analyzed
by using a Matlab (Mathworks) program. In the force trajectory,
the amplitude of beating peaks provided the measurement of cell
beating force.
Statistical Analysis
Data were presented as the mean 6 standard deviation. A two-
way analysis of variance (ANOVA) was performed to compare the
percentage of contractile EBs and gene expression levels between
control and experimental groups. The Tukey-Kramer post-hoc
test was used for all pair-wise comparisons and statistical
significance was set at p,0.05. All statistical analyses were
performed using the JMP statistical software package (SAS
Institute, Cavy, NC).
Results
Effects of Apelin on Mouse and Human ESCs
Apelin concentration was optimized to establish a robust
cardiac differentiation protocol. The contractile mEBs were seen
as early as day 6 as shown in Figure 2A. The percentage of
contractile EBs in all groups peaked around day 14, plateaued
around day 16, and decreased around day 18. Compared to
control, apelin significantly increased the percentage of contractile
EBs in all dosages (p,0.05). Addition of 100 nM of apelin was
found to show the highest percentage of beating mESC-derived
EBs (mEBs) compared to 50 and 500 nM in concentrations
(p,0.05). Immunohistochemistry on single cells derived from
100 nM apelin treated mEBs showed positive production of
cardiac troponin-T and a-actinin after 14 days (Fig. 2B). Gene
expression analyses revealed up-regulation of Nkx2.5, Isl1 and
GATA4, the early cardiac differentiation transcriptional factors,
with apelin treatment as early as day 3 (Fig. 2C). The expression of
APJ also increased significantly with apelin treatment (Fig. 2C).
The chronotropic effects of the cardiotonic drugs on the in vitro
function of mEBs between control and apelin treated groups were
investigated as shown in Figure 3. Significant negative chrono-
tropic effect on the EBs was observed after the addition of
diltiazem, a calcium channel blocker. All contracting EBs ceased
to beat at concentration of 10
25 M and no difference was found
between apelin and control groups (Fig. 3A). When positive
chronotropic effect of isoprenaline, a b1-adrenoreceptor agonist,
was tested, significant increase in the contractile frequency was
demonstrated by both control and apelin treated groups. Apelin-
treated group showed significantly higher contractile frequency
compared to the control group at isoprenaline dose of 10
25 M
(Fig. 3B).
Similarly, the effects of apelin only on hESC cardiac differen-
tiation were evaluated and the optimal dosage for promoting
cardiac differentiation for hESCs was determined. Plated hESC-
derived EBs (hEBs) demonstrated contractility as early as day 14 as
shown in Figure 4A. The percentage of contractile hEBs in all
groups peaked around day 21 and plateaued afterwards. As shown
in Figure 4A, a dose dependent difference on the percentage of
contractile hEBs was observed in the apelin-only treatment groups.
The 500 nM apelin-treated group exhibited the highest percent-
age of contractile hEBs compared to other concentrations.
Consequently, the optimal apelin concentration for establishing
a robust cardiac differentiation protocol for hESCs was chosen at
500 nM. This concentration was used to assess the synergistic
effects of apelin with Protocols A and B. Positive production of
cTNT, connexin-43, and a-sarcomeric actinin by hEBs was found
in the apelin treated group after 21 days by immunohistochemistry
(Fig. 4B).
Synergistic Effects of Apelin with BMP-4, Activin-A and
bFGF on Human ESCs
In order to establish a robust cardiac differentiation protocol,
500 nM of apelin was combined with other reported mesodermal
growth factors for cardiac differentiation (Fig. 1) [16]. When apelin
was combined with Protocol A (Combined Protocol A), which
includes a long-term exposure of 20% fetal bovine serum (FBS) in
the basal culture media, hEBs demonstrated contractility as early
as day 14 while other treatment groups started beating after 16–18
days as shown in Figure 4A. Interestingly, after 21 days, hEBs in
the Combined Protocol A demonstrated significantly higher
percentage of contractile hEBs compared to the basal media
control group, apelin only group, and Protocol A (Fig. 4A).
Positive production of mature cardiac markers was also found
(Fig. 4B). Gene expression of pre-mesodermal marker Mesp-1,
early cardiac differentiation marker Nkx2.5, and mature cardiac
markers ANP, cTNT, MLC and MHC were quantified over the
cell culture period (Fig. 5). The expression of Mesp-1 decreased
after 6 days of differentiation in all groups compared to day 0, and
was diminished after 32 days except for the basal media
differentiation group (Fig. 5). Expression of early cardiac
transcriptional factor, Nkx2.5, increased over time for all groups,
and was observably up-regulated in the Combined Protocol A
compared to all the others after 16 days (Fig. 5). Expression of all
mature cardiac markers including ANP, cTNT, MLC and MHC
increased over time for all groups. Combined Protocol A
significantly increased the gene expression of these mature cardiac
markers (Fig. 5).
In order to eliminate the confounding biochemical effects of
FBS, the synergistic effects of apelin on cardiac differentiation
were further evaluated in combination with serum-reduced
Protocol B (Combined Protocol B). It was found that the
Combined Protocol B up-regulated the gene expression of cTNT
in comparison to Protocol B. This effect of apelin was observed as
early as day 5 of the cardiac differentiation (Fig. 6A). The
percentage of cTNT
+ positive cells in culture also increased over
time and the addition of apelin significantly increased the cTNT
+
cells in culture (Fig. 6B). Furthermore, the imaging of Ca
2+
transients in contractile single cardiac cells in Protocol B vs.
Combined Protocol B groups demonstrated characteristic Ca2+
transient and no difference in the contractile frequency or Ca
2+
transient amplitude between the 2 groups (Fig. 6C). Interestingly,
atomic force microscopy data showed significantly higher peak
contractile force in the Combined Protocol B compared to
Protocol B (Fig. 6D).
Discussion
We determined the role of apelin-13 (apelin) on cardiac
differentiation of mESCs and hESCs and assessed its synergistic
effects at both cellular and molecular levels. The optimal dosage of
Apelin Promotes ESC Cardiac Differentiation
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examined initially. Then a cardiac differentiation protocol in-
cluding apelin and mesodermal differentiation factors (BMP-4,
activin-A, and bFGF) was established by administering them in
a developmentally specific temporal sequence. This study found
that apelin promoted cardiac differentiation of both mouse and
human ESCs. Furthermore, this novel peptide exerted synergistic
effects on the differentiation efficiency when treated with
mesodermal differentiation factors and generated a rich homoge-
neous pool of cardiac cells from the ESCs.
The effects of apelin on the ESCs were initially evaluated
through the ability to produce more contractile EBs. The
contractile mEBs appeared following 6 days of exposure to apelin,
which was significantly earlier than the control group containing
20% FBS. Similarly, an increased percentage of contractile hEBs
by apelin was also found. These findings could be attributed to the
apelin-induced migration and aggregation of ESCs committed to
cardiac lineage, allowing homotypic cellular interactions of
mesodermally fated EBs to enhance cardiac differentiation. The
2 populations of cardiac progenitor cells in the development of
primary and secondary heart fields are known to migrate and
interact to develop into the heart and great vessels [27–31].
Myocardial regulatory genes that are activated in both lineages
include Gata4-6 (zinc-finger-containing transcription factors of the
GATA family), Nkx2.5 (development of first and secondary heart
fields), and Isl1 (key transcriptional regulators in the secondary
heart field) [32–34]. This study demonstrated up-regulation of
GATA4, Nkx2.5, and Isl1, indicating enhancement of early
cardiac differentiation transcriptional activity. Apelin enhanced
the expression of Isl1 on day 3 and both GATA4 and NKX2.5
after day 5 of culture in the mESCs. These findings support the
role of apelin in the migration of cardiac progenitor cells into the
development of both heart fields. This effect of apelin was
confirmed by the higher percentage of cTNT
+, connexin-43, and
a-sarcomeric actin in the apelin-treated EBs, indicating increased
homogeneity of the cardiac lineage committed cells.
The study then sought to determine the synergistic effects of
apelin in enhancing the cardiac differentiation efficiency of 2
protocols employing mesodermal differentiation factors [13,16].
Compared to apelin or the two protocols alone, the administration
of apelin, BMP-4, activin-A and bFGF significantly enhanced the
cardiac differentiation efficiency. Higher percentage of contractile
EBs, up-regulation of early and mature cardiac markers, and
increased percentage of cTNT
+ cells confirmed the synergistic
effect of apelin in promoting cardiac differentiation. The presence
of apelin appears to have promoted the recruitment and
aggregation of mesodermally committed progenitor cells [27].
Although induced contractility was not found, a previously
published study reported another mechanism involving the up-
regulation of myosin light chain 2 L gene expression by apelin
[35]. The report suggested that the apelin/APJ signaling was
possibly through mitogen-activated protein kinase/p70S6 pathway
downstream of Cripto [35]. In other studies, it was demonstrated
that apelin did not modulate L-type Ca
2+ or voltage-activated K
+
currents in isolated adult rat ventricular myocytes and did not
change the intracellular baseline calcium level [36,37]. These data
are consistent with this study’s findings regarding the Ca
2+
transient data in which the exposure of apelin on hESCs
significantly increased the peak contractile force while the Ca
2+
transient remained unchanged. Other studies found that apelin-13
was the predominant isoform in cardiac tissue and the most potent
endogenous inotropic agents tested [38,39]. Addition of apelin was
shown to increase the sarcomere shortening by 1.4 fold in single
mature cardiomyocytes resulting in increased contractility of
a whole rat heart and the atrial strips [40]. These results support
our finding that apelin not only enhanced the differentiation and
maturation of ESC-derived cardiac cells, but also enhanced their
contractile function. Although the mechanism of inotropic actions
of apelin remains unclear, it has been found to be independent of
angiotensin II, endothelin-1, catecholamines and nitric oxide
release [37]. Some studies suggested that it might be related to the
increased availability of activator Ca
2+ and/or increased Ca
2+
responsiveness [38,39]. Although some studies reported a marginal
increase in calcium transient in mature cardiomyocytes with the
addition of apelin in vitro, many studies have found no effect of
apelin on Ca
2+ availability [36,37,39,41]. Finally, It was reported
that the effect of apelin on rat myocyte contractility was modulated
through the sacrolemmal sodium-hydrogen ion exchanger which
led to sensitization of myofilaments to Ca
2+[42]. These findings
are consistent with our data that the Ca
2+ transient did not change
between the apelin-treated and non-treated groups.
In conclusion, this study demonstrated that apelin enhanced
cardiac differentiation when combined with the mesodermal
differentiation factors, BMP-4, activin-A and bFGF. The un-
derlying mechanism could be attributed to the recruitment and
enhanced aggregation of the mesodermal progenitor cells. The
Combined Protocols A and B systematically generated a more
homogeneous population of cardiac lineage committed cells.
Isolation of the cells at an earlier time point may possibly yield
a pool of cardiac lineage committed progenitor cells. Future
studies will establish an effective cell sorting strategy to select the
cardiac progenitor cells.
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